Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 10/20 | 0.34 |
| ▸ | F7 | P08709 | 10/20 | 0.34 |
| ▸ | F10 | P00742 | 9/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAP2 | P11137 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11027705 | 0.91 | F11 (0.35) | F11F7F10HTTBRD4 | |
| SCHEMBL11028093 | 0.88 | PARP1 (0.32) | F11F7F10IKBKBGAA | |
| SCHEMBL11940909 | 0.83 | AURKA (0.37) | KDM4EUSP2 | |
| SCHEMBL11030190 | 0.82 | HTR1A (0.36) | F11F7F10KDM4EALDH1A1 | |
| SCHEMBL11025415 | 0.79 | CYP2C19 (0.41) | BRD4CREBBPALDH1A1MAP2PARP1 | |
| SCHEMBL11025280 | 0.77 | PRKAG1 (0.37) | F11F7F10ALDH1A1PARP1 | |
| SCHEMBL11031117 | 0.77 | HTT (0.31) | HTT | |
| SCHEMBL11025566 | 0.75 | MEN1 (0.37) | HTTKDM4EALDH1A1GAA | |
| SCHEMBL2138997 | 0.74 | TSHR (0.39) | F11F7F10PDK2KDM4E | |
| SCHEMBL11021499 | 0.73 | ALDH1A1 (0.39) | F11F7F10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | F11 2989/4885F7 2297/4885F10 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.